

Yohei Sotomi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6015213/publications.pdf>

Version: 2024-02-01

104
papers

2,960
citations

186254

28
h-index

182417

51
g-index

105
all docs

105
docs citations

105
times ranked

3271
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantitative Validation of the Coronary Angioscopic Yellow Plaque with Lipid Core Burden Index Assessed by Intracoronary Near-Infrared Spectroscopy. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 362-369.	2.0	5
2	Practical Assessment of the Tradeoff between Fatal Bleeding and Coronary Thrombotic Risks using the Academic Research Consortium for High Bleeding Risk Criteria. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 1236-1248.	2.0	9
3	Sex-related difference in bleeding and thromboembolic risks in patients with atrial fibrillation treated with direct oral anticoagulants. <i>Heart and Vessels</i> , 2022, 37, 467-475.	1.2	4
4	Comparison of Low-Dose Direct Oral Anticoagulants for Patients <80 Versus ≥80 Years of Age With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2022, 162, 86-91.	1.6	3
5	Phenotyping of acute decompensated heart failure with preserved ejection fraction. <i>Heart</i> , 2022, 108, 1553-1561.	2.9	8
6	Minimal subphenotyping model for acute heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2022, 9, 2738-2746.	3.1	4
7	What Are Your Expectations for Risk Prediction Tools?. <i>JACC Asia</i> , 2022, 2, 351-353.	1.5	1
8	Dose of Direct Oral Anticoagulants and Adverse Outcomes in Asia. <i>American Journal of Cardiology</i> , 2021, 139, 50-56.	1.6	13
9	Comparable neointimal healing in patients with stable coronary lesions and acute coronary syndrome: 3-month optical coherence tomography analysis. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 2095-2105.	1.5	4
10	Alternative Echocardiographic Algorithm for Left Ventricular Filling Pressure in Patients With Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2021, 143, 80-88.	1.6	2
11	Prevalence of the Japanese high bleeding risk criteria and its prognostic significance for fatal bleeding in patients with acute myocardial infarction. <i>Heart and Vessels</i> , 2021, 36, 1484-1495.	1.2	9
12	Sex Differences in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e018574.	3.7	85
13	Prognostic significance of dipstick proteinuria in heart failure with preserved ejection fraction: insight from the PURSUIT-HFpEF registry. <i>BMJ Open</i> , 2021, 11, e049371.	1.9	3
14	Randomised controlled trial to investigate optimal antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: a study protocol of the OPTIMA-AF trial. <i>BMJ Open</i> , 2021, 11, e048354.	1.9	2
15	The impact of plaque type on strut embedment/protrusion and shear stress distribution in bioresorbable scaffold. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 454-462.	1.2	5
16	Serial optical coherence tomography and angioscopic assessments of 10-year in-stent restenosis of Cypher sirolimus-eluting stent treated with drug-coated balloon angioplasty. <i>Journal of International Medical Research</i> , 2020, 48, 030006051983744.	1.0	0
17	Five-year clinical efficacy and safety of contemporary thin-strut biodegradable polymer versus durable polymer drug-eluting stents: a systematic review and meta-analysis of 9 randomized controlled trials. <i>Cardiovascular Intervention and Therapeutics</i> , 2020, 35, 250-258.	2.3	20
18	Neointimal characteristics comparison between biodegradable-polymer and durable-polymer drug-eluting stents: 3-month follow-up optical coherence tomography light property analysis from the RESTORE registry. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 205-215.	1.5	5

#	ARTICLE	IF	CITATIONS
19	Dynamic Change of Coronary Microcirculation During Cardiocirculatory Support by the Impella. JACC: Cardiovascular Interventions, 2020, 13, 135-137.	2.9	5
20	The influence of implantation techniques on lesion oriented-outcomes in Absorb BVS and Xience EES lesions treated in routine clinical practice at complete three year follow-up: AIDA trial QCA substudy. International Journal of Cardiovascular Imaging, 2020, 36, 565-575.	1.5	0
21	Impact of diabetes mellitus on the early-phase arterial healing after drug-eluting stent implantation. Cardiovascular Diabetology, 2020, 19, 203.	6.8	6
22	Persistent Systemic Inflammation Is Associated With Bleeding Risk in Atrial Fibrillation Patients. Circulation Journal, 2020, 84, 411-418.	1.6	17
23	Impact of Direct Oral Anticoagulant Off-Label Reduced Dose in Combination With Antiplatelet Agents on Clinical Outcome—Propensity Score-Matching Analysis From the DIRECT Real-World Non-Valvular Atrial Fibrillation Registry. Circulation Reports, 2020, 2, 289-296.	1.0	9
24	External Validation of the ORBIT Bleeding Score and the HAS-BLED Score in Nonvalvular Atrial Fibrillation Patients Using Direct Oral Anticoagulants (Asian Data from the DIRECT Registry). American Journal of Cardiology, 2019, 124, 1044-1048.	1.6	19
25	Serial Optical Coherence Tomography at Baseline, 7 Days, and 1, 3, 6 and 12 Months After Bioresorbable Scaffold Implantation in a Growing Porcine Model. Circulation Journal, 2019, 83, 556-566.	1.6	1
26	Early vessel healing after implantation of biodegradable-polymer and durable-polymer drug-eluting stent: 3-month angiographic evaluation of the RESTORE registry. International Journal of Cardiovascular Imaging, 2019, 35, 973-980.	1.5	8
27	The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial. International Journal of Cardiovascular Imaging, 2019, 35, 1189-1198.	1.5	6
28	Bleeding Risk of Add-On Anti-Platelet Agents to Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation (From 2216 Patients in the DIRECT Registry). American Journal of Cardiology, 2019, 123, 1293-1300.	1.6	16
29	Impact of the one-year angiographic findings on long-term clinical events in 504 patients treated with first-generation or second-generation drug-eluting stents: the DESNOTE-X study. EuroIntervention, 2019, 15, 631-639.	3.2	13
30	hemodynamic analysis of a novel bioresorbable scaffold in porcine coronary artery model. Catheterization and Cardiovascular Interventions, 2018, 91, 1084-1091.	1.7	5
31	Endothelial shear stress 5 years after implantation of a coronary bioresorbable scaffold. European Heart Journal, 2018, 39, 1602-1609.	2.2	33
32	Fate of Different Types of Intrastent Tissue Protrusion. JACC: Cardiovascular Interventions, 2018, 11, 95-97.	2.9	8
33	Coronary calcification as a mechanism of plaque/media shrinkage in vessels treated with bioresorbable vascular scaffold: A multimodality intracoronary imaging study. Atherosclerosis, 2018, 269, 6-13.	0.8	10
34	Right Hemothorax Caused by Septal Puncture During Catheter Ablation for Atrial Fibrillation. JACC: Clinical Electrophysiology, 2018, 4, 555-556.	3.2	4
35	Fate of post-procedural malapposition of everolimus-eluting polymeric bioresorbable scaffold and everolimus-eluting cobalt chromium metallic stent in human coronary arteries: sequential assessment with optical coherence tomography in ABSORB Japan trial. European Heart Journal Cardiovascular Imaging, 2018, 19, 59-66.	1.2	21
36	Imaging assessment of bioresorbable vascular scaffolds. Cardiovascular Intervention and Therapeutics, 2018, 33, 11-22.	2.3	9

#	ARTICLE	IF	CITATIONS
37	Histopathologic Insights Into the Honeycomb-Like Structure in the Coronary Artery. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, e157-e159.	2.9	8
38	First-in-Man Trial of SiO ₂ Inert-Coated Bare Metal Stent System in Native Coronary Stenosis—The AXETIS FIM Trial. <i>Circulation Journal</i> , 2018, 82, 477-485.	1.6	3
39	Quality difference of neointima following the implantation of everolimus-eluting bioresorbable scaffolds and metallic stents in patients with ST-elevation myocardial infarction: quantitative assessments by light intensity, light attenuation, and backscatter on optical coherence tomography in the TROFI II trial. <i>EuroIntervention</i> , 2018, 14, 678-685.	3.2	12
40	A simplified and reproducible method to size the mitral annulus: implications for transcatheter mitral valve replacement. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, jew132.	1.2	17
41	Predictors of long-term outcomes after bypass grafting versus drug-eluting stent implantation for left main or multivessel coronary artery disease. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 177-185.	1.7	7
42	Impact of revascularization of coronary chronic total occlusion on left ventricular function and electrical stability: analysis by speckle tracking echocardiography and signal-averaged electrocardiogram. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 815-823.	1.5	12
43	Intracoronary optical coherence tomography: Clinical and research applications and intravascular imaging software overview. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 679-689.	1.7	17
44	Outcomes of Coronary Artery Bypass Graft Surgery Versus Drug-Eluting Stents in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 625-630.	2.6	11
45	Single or dual antiplatelet therapy after PCI. <i>Nature Reviews Cardiology</i> , 2017, 14, 294-303.	13.7	35
46	Coronary bypass surgery versus stenting in multivessel disease involving the proximal left anterior descending coronary artery. <i>Heart</i> , 2017, 103, 428-433.	2.9	19
47	Bioresorbable Scaffold. <i>Circulation Research</i> , 2017, 120, 1341-1352.	4.5	129
48	Vasomotor Response to Nitroglycerine Over 5 Years Follow-Up After Everolimus-Eluting Bioresorbable Scaffold Implantation. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 786-795.	2.9	17
49	Bioresorbable vascular scaffolds and late lumen loss — Authors' reply. <i>Lancet, The</i> , 2017, 389, 1797-1798.	13.7	0
50	Geographical Difference of the Interaction of Sex With Treatment Strategy in Patients With Multivessel Disease and Left Main Disease. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	31
51	Comparison of Outcome of Coronary Artery Bypass Grafting Versus Drug-Eluting Stent Implantation for Non-ST-Elevation Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2017, 120, 380-386.	1.6	48
52	Strut protrusion and shape impact on endothelial shear stress: insights from pre-clinical study comparing Mirage and Absorb bioresorbable scaffolds. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 1313-1322.	1.5	23
53	Impact of the SYNTAX scores I and II in patients with diabetes and multivessel coronary disease: a pooled analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST trials. <i>European Heart Journal</i> , 2017, 38, 1969-1977.	2.2	76
54	Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials. <i>European Heart Journal</i> , 2017, 38, 2559-2566.	2.2	42

#	ARTICLE	IF	CITATIONS
55	Accuracy of coronary computed tomography angiography for bioresorbable scaffold luminal investigation: a comparison with optical coherence tomography. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 431-439.	1.5	11
56	Coronary artery bypass graft surgery versus drug-eluting stent implantation for high-surgical-risk patients with left main or multivessel coronary artery disease. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 51, 943-949.	1.4	2
57	Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1115-1130.	2.9	32
58	Serial Assessment of Tissue Precursors and Progression of Coronary Calcification Analyzed by Fusion of IVUS and OCT. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 1151-1161.	5.3	31
59	Comparative assessment of plaque/media change on three modalities of IVUS immediately after implantation of either everolimus-eluting bioresorbable vascular scaffold or everolimus-eluting metallic stent in Absorb II study. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 441-449.	1.5	3
60	Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1867-1877.	2.9	13
61	Serial 5-Year Evaluation of Side Branches Jailed by Bioresorbable Vascular Scaffolds Using 3-Dimensional Optical Coherence Tomography. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	7
62	The Effect of Strut Protrusion on Shear Stress Distribution. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1803-1805.	2.9	8
63	Comparison of Stenting Versus Bypass Surgery According to the Completeness of Revascularization in Severe Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1415-1424.	2.9	95
64	Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents. <i>Journal of the American College of Cardiology</i> , 2017, 70, 60-74.	2.8	51
65	Assessment of the hemodynamic characteristics of Absorb BVS in a porcine coronary artery model. <i>International Journal of Cardiology</i> , 2017, 227, 467-473.	1.7	13
66	Impact of Multivessel Coronary Artery Disease With Versus Without Left Main Coronary Artery Disease on Long-Term Mortality After Coronary Bypass Grafting Versus Drug-Eluting Stent Implantation. <i>American Journal of Cardiology</i> , 2017, 119, 225-230.	1.6	11
67	Tissue characterization with depth-resolved attenuation coefficient and backscatter term in intravascular optical coherence tomography images. <i>Journal of Biomedical Optics</i> , 2017, 22, 1.	2.6	42
68	Possible mechanical causes of scaffold thrombosis: insights from case reports with intracoronary imaging. <i>EuroIntervention</i> , 2017, 12, 1747-1756.	3.2	108
69	Does acute coronary syndrome impact on the incidence of thrombosis after the implantation of an Absorb bioresorbable vascular scaffold?. <i>EuroIntervention</i> , 2017, 12, 2025-2027.	3.2	4
70	Is quantitative coronary angiography reliable in assessing the late lumen loss of the everolimus-eluting bioresorbable polylactide scaffold in comparison with the cobalt-chromium metallic stent?. <i>EuroIntervention</i> , 2017, 13, e585-e594.	3.2	6
71	Coronary stent thrombosis: what have we learned?. <i>Journal of Thoracic Disease</i> , 2016, 8, 1398-1405.	1.4	12
72	Coronary Artery Bypass Surgery Versus Drug-Eluting Stent Implantation for Left Main or Multivessel Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2481-2489.	2.9	42

#	ARTICLE	IF	CITATIONS
73	Clinical impact of contact force and its regional variability on efficiency and effectiveness of pulmonary vein isolation for atrial fibrillation. <i>Journal of Cardiology</i> , 2016, 68, 335-341.	1.9	6
74	Individual Long-Term Mortality Prediction Following Either Coronary Stenting or Bypass Surgery in Patients With Multivessel and/or Unprotected Left Main Disease. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1564-1572.	2.9	45
75	Outcomes After Percutaneous Coronary Intervention or Bypass Surgery in Patients With Unprotected Left Main Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 999-1009.	2.8	95
76	Impact of Implantation Technique and Plaque Morphology on Strut Embedment and Scaffold Expansion of Polylactide Bioresorbable Scaffold – Insights From ABSORB Japan Trial. <i>Circulation Journal</i> , 2016, 80, 2317-2326.	1.6	28
77	Promising, but still a matter of debate. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 378-379.	1.7	1
78	Optimisation of percutaneous coronary intervention: indispensables for bioresorbable scaffolds. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 1053-1070.	1.5	2
79	Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. <i>Lancet</i> , The, 2016, 388, 2479-2491.	13.7	451
80	Acute Gain in Minimal Lumen Area Following Implantation of Everolimus-Eluting ABSORB Biodegradable Vascular Scaffolds or Xience Metallic Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1216-1227.	2.9	18
81	Long-Term Mortality After Coronary Revascularization in Nondiabetic Patients With Multivessel Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 29-36.	2.8	52
82	Quantitative assessment of the stent/scaffold strut embedment analysis by optical coherence tomography. <i>International Journal of Cardiovascular Imaging</i> , 2016, 32, 871-883.	1.5	35
83	Bioresorption and Vessel Wall Integration of a Fully Bioresorbable Polymeric Everolimus-Eluting Scaffold. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 838-851.	2.9	31
84	Coronary Artery Bypass Grafting Versus Drug-Eluting Stents Implantation for Previous Myocardial Infarction. <i>American Journal of Cardiology</i> , 2016, 118, 17-22.	1.6	14
85	The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1231-1242.	2.9	80
86	Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction TROFI II trial. <i>European Heart Journal</i> , 2016, 37, 229-240.	2.2	197
87	From drug eluting stents to bioresorbable scaffolds; to new horizons in PCI. <i>Expert Review of Medical Devices</i> , 2016, 13, 271-286.	2.8	29
88	Bioresorbable drug-eluting scaffolds for treatment of vascular disease. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 725-739.	5.0	3
89	Progression of calcification after implantation of a fully bioresorbable scaffold: A serial and combined IVUS-OCT follow-up of 5years. <i>International Journal of Cardiology</i> , 2016, 209, 176-178.	1.7	1
90	Patient Selection and Procedural Considerations for Coronary Orbital Atherectomy System. <i>Interventional Cardiology Review</i> , 2016, 11, 33.	1.6	28

#	ARTICLE	IF	CITATIONS
91	Tools and Techniques - Clinical: SYNTAX score II calculator. EuroIntervention, 2016, 12, 120-123.	3.2	12
92	Is quantitative coronary angiography reliable in assessing the lumen gain after treatment with the everolimus-eluting bioresorbable poly(lactide) scaffold?. EuroIntervention, 2016, 12, e998-e1008.	3.2	16
93	Quantification by optical coherence tomography imaging of the ablation volume obtained with the Orbital Atherectomy System in calcified coronary lesions. EuroIntervention, 2016, 12, 1126-1134.	3.2	25
94	Comparative analysis method of permanent metallic stents (XIENCE) and bioresorbable poly-L-lactic (PLLA) scaffolds (Absorb) on optical coherence tomography at baseline and follow-up. EuroIntervention, 2016, 12, 1498-1509.	3.2	51
95	Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. EuroIntervention, 2016, 12, 1090-1101.	3.2	127
96	Relation Between Bioresorbable Scaffold Sizing Using QCA-Dmax and Clinical Outcomes at 1 Year in 1,232 Patients From 3 Study Cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). JACC: Cardiovascular Interventions, 2015, 8, 1715-1726.	2.9	50
97	Impact of the Orbital Atherectomy System on a Peripheral Calcified Lesion. JACC: Cardiovascular Interventions, 2015, 8, e205-e206.	2.9	5
98	Persistent left atrial remodeling after catheter ablation for non-paroxysmal atrial fibrillation is associated with very late recurrence. Journal of Cardiology, 2015, 66, 370-376.	1.9	16
99	Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use. Expert Review of Cardiovascular Therapy, 2015, 13, 1127-1145.	1.5	11
100	Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent. JACC: Cardiovascular Interventions, 2015, 8, 1053-1063.	2.9	36
101	Impact of the orbital atherectomy system on a coronary calcified lesion: quantitative analysis by light attenuation in optical coherence tomography. EuroIntervention, 2015, 11, e1-e1.	3.2	3
102	Regional Difference of Optimal Contact Force to Prevent Acute Pulmonary Vein Reconnection During Radiofrequency Catheter Ablation for Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2014, 25, 941-947.	1.7	29
103	Cause of Very Late Recurrence of Atrial Fibrillation or Flutter After Catheter Ablation for Atrial Fibrillation. American Journal of Cardiology, 2013, 111, 552-556.	1.6	53
104	Incidence and risk factors for very late recurrence of atrial fibrillation after radiofrequency catheter ablation. Europace, 2013, 15, 1581-1586.	1.7	39